These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25385112)

  • 1. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
    Huband MD; Bradford PA; Otterson LG; Basarab GS; Kutschke AC; Giacobbe RA; Patey SA; Alm RA; Johnstone MR; Potter ME; Miller PF; Mueller JP
    Antimicrob Agents Chemother; 2015 Jan; 59(1):467-74. PubMed ID: 25385112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
    Biedenbach DJ; Huband MD; Hackel M; de Jonge BL; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6053-63. PubMed ID: 26195518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
    Alm RA; Lahiri SD; Kutschke A; Otterson LG; McLaughlin RE; Whiteaker JD; Lewis LA; Su X; Huband MD; Gardner H; Mueller JP
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1478-86. PubMed ID: 25534723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
    Jacobsson S; Golparian D; Alm RA; Huband M; Mueller J; Jensen JS; Ohnishi M; Unemo M
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5585-8. PubMed ID: 24982070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between Zoliflodacin and
    Collins JA; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2024 Aug; 10(8):3071-3082. PubMed ID: 39082980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
    Su XH; Wang BX; Le WJ; Liu YR; Wan C; Li S; Alm RA; Mueller JP; Rice PA
    Antimicrob Agents Chemother; 2016 Jan; 60(1):621-3. PubMed ID: 26482313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
    Kohlhoff SA; Huband MD; Hammerschlag MR
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
    Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
    D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
    PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
    Unemo M; Ringlander J; Wiggins C; Fredlund H; Jacobsson S; Cole M
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5220-5. PubMed ID: 26077246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.
    Butler MM; Lamarr WA; Foster KA; Barnes MH; Skow DJ; Lyden PT; Kustigian LM; Zhi C; Brown NC; Wright GE; Bowlin TL
    Antimicrob Agents Chemother; 2007 Jan; 51(1):119-27. PubMed ID: 17074800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
    Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
    J Antimicrob Chemother; 2010 Jul; 65(7):1441-7. PubMed ID: 20435780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of
    Pisano L; Giovannuzzi S; Supuran CT
    Expert Opin Ther Pat; 2024 Jun; 34(6):511-524. PubMed ID: 38856987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
    Waites KB; Crabb DM; Duffy LB; Huband MD
    Antimicrob Agents Chemother; 2015; 59(6):3627-9. PubMed ID: 25824220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
    Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
    Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel DNA gyrase inhibitors: microbiological characterisation of pyrrolamides.
    Uria-Nickelsen M; Blodgett A; Kamp H; Eakin A; Sherer B; Green O
    Int J Antimicrob Agents; 2013 Jan; 41(1):28-35. PubMed ID: 23142086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
    Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.